3 Dividend Stocks to Hold for the Next 10 Years

The article argues that Merck, Verizon, and Equinix are attractive 10-year dividend holdings, highlighting Merck’s pipeline and acquisition-led efforts to offset Keytruda’s patent loss, Verizon’s 6% forward yield and growth in fixed wireless access and AI networking, and Equinix’s AI data center exposure with $2.44 billion in quarterly revenue up 10% year over year. It emphasizes long-term cash flow, recurring revenue, and dividend growth rather than near-term catalysts. The piece is primarily a bullish stock-picking commentary and is unlikely to move the market broadly.

Analysis

The market is still treating these as three separate dividend stories, but the real common thread is balance-sheet monetization of scarce infrastructure: patent-protected biologic cash flows, spectrum/last-mile connectivity, and data-center interconnectivity. That matters because each name is effectively buying time with recurring revenue, and the market usually underwrites that time too cheaply until the inflection becomes visible in reported growth. The setup is most attractive where the asset base is hard to replicate and where capital returns can continue even if top-line growth slows.

VZ looks like the cleanest cash-yield vehicle, but the underappreciated angle is that FWA and AI networking create a second growth layer that can offset the mature wireless core without requiring a full re-rating. The risk is not demand collapse; it’s price competition or capex creep that quietly compresses free cash flow and forces the dividend multiple lower before investors notice. EQIX is the highest-quality AI beneficiary here, but the market may be overpaying for the growth duration: the stock is levered to sustained data-center scarcity, so any normalization in colocation supply or hyperscaler insourcing could hit valuation faster than operations.

For MRK, the key second-order effect is that patent expiry is a timing problem more than a terminal-value problem if pipeline conversion is real. The market is likely discounting too much of the post-Keytruda bridge because biotech execution risk is lumpy, but that also creates upside if one or two late-stage assets read through cleanly over the next 12-24 months. TERN is a call option on M&A/clinical success rather than a standalone conviction name; its main catalyst is not revenue, but de-risking into a larger balance sheet sponsor. The contrarian view is that the dividend basket is not just defensive — it is a hidden AI/healthcare compounder sleeve, and the best risk/reward may come from owning the “boring” infra names while the market keeps chasing the obvious AI winners.

Key Decisions for Investors

• Long VZ on weakness for a 6-12 month total-return trade: target high-single-digit upside plus ~6% yield; thesis breaks if FWA net adds stall for two consecutive quarters or pricing pressure forces capex up.
• Initiate EQIX as a core long, but size below a full position: 12-18 month hold for recurring cash-flow compounding; upside comes from continued AI colocation scarcity, while downside is valuation compression if hyperscalers slow leasing demand.
• Pair trade: long VZ / short a basket of low-quality telecom cyclicals over 3-6 months; VZ has the better dividend durability and multiple support, while peers with weaker balance sheets are more exposed if rates stay higher for longer.
• Buy MRK on a staged basis into any post-news pullback: 12-24 month horizon, with the re-rating driven by pipeline milestones rather than Keytruda headlines; risk/reward improves if the market remains fixated on patent cliffs and underprices portfolio replacement.
• Speculative side position: TERN as an event-driven optionality trade only, sized small; treat it as a 6-18 month M&A/clinical catalyst rather than a fundamental long, with binary downside if development data disappoints.